"The Forge Therapeutics platform is truly transformational providing novel chemistry solutions to high value targets that have lacked suitable approaches until now," said Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics. "This prestigious national chemistry award and our recent Federal funding provides further validation of our innovative approach for first-in-class and best-in-class medicines."
To learn more about 2016 National Award recipients please visit: https://www.acs.org/content/acs/en/funding-and-awards/awards/national/recipients/2016-national-award-recipients.html
About Forge Therapeutics, Inc.
Forge Therapeutics, Inc. ("Forge") is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins. Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body. Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins. The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team). Forge Therapeutics, Inc., maintains its headquarters in San Diego, California. To learn more please visit www.ForgeTherapeutics.com.
Logo - http://photos.prnewswire.com/prnh/20150807/256906LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/forge-therapeutics-scientific-co-founder-awarded-national-chemistry-honor-300313694.html
SOURCE Forge Therapeutics, Inc.